Pulmonary Allergy Drugs Advisory Committee
September 6, 2002
Holiday Inn Gaithersburg
7:30 Introductions Dr. Mark Dykewicz
COI Ms. Kimberly L. Topper
Welcome Dr. Robert Meyer
Dr. Badrul Chowdhury
8:00 Boehringer Ingelheim Presentation's
Introduction and Overview Dr. Burkhard Blank
Bronchodilator Efficacy in COPD Dr. Bernd Disse
Quantification of Dyspnea Dr. Paul Jones
Dyspnea and Related Measures Dr. Theodore Witek
Clinical Safety Evaluation Dr. Steven Kesten
Clinical Perspective Dr. James Donohue
Conclusions Dr. Burkhard Blank
9:30 Break
9:45 Food and Drug Administration Presentation's
Transition Dyspnea Index (TDI) Dr. Lisa Kammerman
PK/PD, Safety & Efficacy Dr. Eugene Sullivan
11:15 General Discussion and Clarification
12:00 Lunch
1:00 Open Public Hearing
2:00 Discussion of Questions
3:30 Adjourn